ClinicalTrials.gg
CompletedNCT06108544Updated Nov 20, 2025

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

A Phase 3 interventional study of TAK-279 and Placebo in Plaque Psoriasis, sponsored by Takeda. Completed at 217 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
28th of 673
1,108 · median 77
Started
2023
with 31 others
Phase 3
188 of 764
6 open now
Registered
702nd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 28th largest by enrollment of the 673 interventional ones that give a count, is one of 32 that started in 2023, is one of 188 in phase 3, and was the 702nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.

Read the detailed description

The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis.

The study will enroll approximately 1000 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups for TAK-279, placebo, or apremilast in a ratio of 2:1:1 which will remain undisclosed to the patient and investigator during the study (unless there is an urgent medical need):

  • TAK-279
  • Apremilast
  • Placebo

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 69 weeks. Participants will go through a screening process to make sure they meet the rules for taking part in the study. This will take up to 35 days. If participants meet the study rules, they will be treated for up to 60 weeks. There will be a safety follow-up visit 4 weeks after their last day of treatment.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Drug Therapy
  • Latitude Psoriasis 2, Latitude Research Program
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Plaque psoriasis for at least 6 months.
  2. Moderate to severe disease.
  3. Candidate for phototherapy or systemic therapy.

Exclusion criteria

Exclusion Criteria:

  1. Other forms of psoriasis.
  2. History of recent infection.
  3. Prior exposure to TAK-279 or active comparator.

Other protocol defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,108 participants (actual)

Study arms

  • Experimental
    TAK-279

    Drug: TAK-279

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Apremilast

    Drug: Apremilast

Interventions

  • Specified drug on specified days.

  • DrugPlacebo

    Specified drug on specified days.

  • Specified drug on specified days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percentage of Participants Achieving 90% Improvement from Baseline in PASI (PASI-90) at Week 16 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Placebo

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' will include all participants who score a 0.

    Time frame: Week 16

  3. Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  4. Percentage of Participants Achieving a Scalp-specific Physician's Global Assessment (ssPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline, Week 16

  5. Percentage of Participants Achieving PASI-75 at Week 4 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 4

  6. Percentage of Participants with a Baseline Dermatology Life Quality Index (DLQI) Score ≥2 who Achieve DLQI Score of 0 or 1 at Week 16 Comparing TAK-279 Against Placebo

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Week 16

  7. Percentage of Participants With a Baseline Psoriasis Symptoms and Signs Diary (PSSD) ≥1 who Achieve Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Placebo

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Week 16

  8. Change from Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 Among Participants With Nail Involvement at Baseline Comparing TAK-279 Against Placebo

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis.

    Time frame: Baseline, Week 16

  9. Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Week 16

  10. Percentage Change from Baseline in BSA Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Week 16

  11. Percentage of Participants Achieving a Physician's Global Assessment (PGA) of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease From Baseline at Week 16 Comparing TAK-279 Against Placebo

    PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1.

    Time frame: Baseline, Week 16

  12. Change from Baseline in DLQI at Week 16 Comparing TAK-279 Against Placebo

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). It will be evaluated for participants with a baseline DLQI score ≥2.

    Time frame: Baseline, Week 16

  13. Change from Baseline in the Short Form-36 Health Survey (SF-36) Version 2 Scores at Week 16 Comparing TAK-279 Against Placebo

    The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the physical component summary (PCS) and mental component summary (MCS), will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL.

    Time frame: Baseline, Week 16

  14. Change from Baseline in the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores at Week 16 Comparing TAK-279 Against Placebo

    EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health.

    Time frame: Baseline, Week 16

  15. Change in Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) Questionnaire Scores at Week 16 Comparing TAK-279 Against Placebo

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Week 16

  16. Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline to Week 16

  17. Percentage of Participants Achieving PASI-75 at Week 16 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  18. Percentage of Participants Achieving PASI-90 at Week 16 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  19. Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline to Week 24

  20. Percentage of Participants Achieving PASI-75 at Week 24 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 24

  21. Percentage of Participants Achieving PASI-90 at Week 24 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 24

  22. Change from Baseline in Weekly Mean PSSD Symptom Score at Week 16 Comparing TAK-279 Against Apremilast

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Baseline to Week 16

  23. Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline to Week 16

  24. Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  25. Percentage of Participants Achieving PASI-100 at Week 24 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 24

  26. Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.

    Time frame: Week 16

  27. Percentage of Participants with a Baseline DLQI Score ≥2 who Achieve DLQI Score of 0/1 at Week 16 Comparing TAK-279 Against Apremilast

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Week 16

  28. Percentage of Participants With a Baseline PSSD ≥1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Apremilast

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Week 16

  29. Change from Baseline in NAPSI Among Participants With Nail Involvement at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis.

    Time frame: Baseline, Weeks 16 and 24

  30. Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline to Week 24

  31. Change from Baseline in DLQI at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Baseline, Weeks 16 and 24

  32. Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Baseline, Weeks 16 and 24

  33. Percent Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Baseline, Weeks 16 and 24

  34. Percentage of Participants Achieving an sPGA of Clear (0) at Week 24 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.

    Time frame: Week 24

  35. Percentage of Participants With a Baseline DLQI Score ≥2 who Achieve a DLQI Score of 0/1 at Week 24 Comparing TAK-279 Against Apremilast

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Week 24

  36. Percentage of Participants With a Baseline PSSD ≥1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 24 Comparing TAK-279 Against Apremilast

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Week 24

  37. Change from Baseline in ssPGA at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline, Weeks 16 and 24

  38. Percentage of Participants Achieving a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease From Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1.

    Time frame: Baseline, Weeks 16 and 24

  39. Change from Baseline in SF-36 Version 2 Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the PCS and MCS, will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL.

    Time frame: Baseline, Weeks 16 and 24

  40. Change from Baseline in the EQ-5D-5L Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health.

    Time frame: Baseline, Weeks 16 and 24

  41. Change from Baseline in the WPAI-PSO Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline, Weeks 16 and 24

  42. Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Weeks 24 and 40 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline, Weeks 24 and 40

  43. Percentage of Participants Achieving PASI-75 at Weeks 24 and 40 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Weeks 24 and 40

  44. Percentage of Participants Achieving PASI-90 at Weeks 24 and 40 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Weeks 24 and 40

  45. Time to Relapse for PASI-75 Responders at Week 40 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Up to Week 60

  46. Percentage of Participants With Maintenance of PASI-75 Response at Week 60 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 60

  47. Percentage of Participants with Maintenance of sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 60 Comparing TAK-279 Against Placebo

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline to Week 60

  48. Percentage of Participants With a Disease Relapse Comparing TAK-279 Against Placebo

    Relapse is defined as a percent change from baseline in PASI score that is at least 50% worse than that observed at Week 40. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Higher scores indicate worsening.

    Time frame: Week 40

  49. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI)

    TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product. An AESI (serious or nonserious) is an adverse event of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator may be appropriate.

    Time frame: Up to week 69

  50. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Time frame: Up to week 69

  51. Number of Participants With Clinically Significant Laboratory Values

    Time frame: Up to week 69

  52. Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings

    Time frame: Up to week 69

07

Study locations

217 sites
  • Total Dermatology
    Birmingham, Alabama 35205, United States
  • Cahaba Dermatology Skin Health Center
    Hoover, Alabama 35244-2111, United States
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006-2722, United States
  • Noble Clinical Research
    Tucson, Arizona 85704-7892, United States
  • Johnson Dermatology Clinic
    Fort Smith, Arkansas 72916-6103, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913-6475, United States
  • Zenith Research, Inc.
    Beverly Hills, California 90211-1705, United States
  • UNISON Clinical Trials (Shahram Jacobs md inc.)
    Encino, California 91436-2428, United States
  • First OC Dermatology Research Inc.
    Fountain Valley, California 92708-3701, United States
  • Long Beach Research Institute, LLC
    Long Beach, California 90805-4587, United States
  • Metropolis Dermatology Downtown LA - Probity - PPDS
    Los Angeles, California 90017-5310, United States
  • Northridge Clinical Trials
    Northridge, California 91325-4122, United States
  • TCR Medical Corporation
    San Diego, California 92123-1523, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • Dermatology Institute and Skin Care Center
    Santa Monica, California 90404-2216, United States
  • Revival Research Corporation - Florida - ClinEdge - PPDS
    Doral, Florida 33122-1902, United States
  • Florida Academic Centers Research
    Miami, Florida 33136-1003, United States
  • San Marcus Research Clinic Inc
    Miami Lakes, Florida 33014-5602, United States
  • FXM Research Miramar
    Miramar, Florida 33027-4714, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172-2741, United States
  • Advanced Clinical Research Institute (ACRI) - Florida
    Tampa, Florida 33607-6429, United States
  • Olympian Clinical Research - 6331 Memorial Hwy
    Tampa, Florida 33615, United States
  • Divine Dermatology and Aesthetics, LLC
    Atlanta, Georgia 30315-2042, United States
  • Advanced Medical Research, PC
    Atlanta, Georgia 30342-1418, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217-3861, United States
  • NorthShore Medical Group Dermatology - Skokie
    Skokie, Illinois 60077-1049, United States
  • DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location
    Clarksville, Indiana 47129-2201, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217-1444, United States
  • DS Research of Kentucky
    Louisville, Kentucky 40241-6162, United States
  • Dermatology & Advanced Aesthetics
    Lake Charles, Louisiana 70605-1213, United States
  • Lawrence J Green, MD LLC
    Rockville, Maryland 20850-6363, United States
  • Allcutis Research LLC
    Beverly, Massachusetts 01915, United States
  • Beacon Clinical Research LLC
    Brockton, Massachusetts 02301, United States
  • David Fivenson MD Dermatology PLLC
    Ann Arbor, Michigan 48103-9746, United States
  • University of Michigan Hospital - 1500 E Medical Center Dr
    Ann Arbor, Michigan 48109-5360, United States
  • Oakland Hills Dermatology - 3400 Auburn Rd
    Auburn Hills, Michigan 48326-3396, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432-3134, United States
  • Skin Specialists PC
    Omaha, Nebraska 68144, United States
  • Vivida Dermatology - Flamingo Rd - Probity - PPDS
    Las Vegas, Nevada 89119-5190, United States
  • ALLCUTIS Research, LLC.
    Portsmouth, New Hampshire 03801-03804, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Mount Sinai Doctors -234 E 85th St
    New York, New York 10029-6504, United States
  • Sadick Research Group
    New York, New York 10075-0385, United States
  • Derm Research Center of NY
    Stony Brook, New York 11790, United States
  • Montefiore Dermatology - BRANY - PPDS
    The Bronx, New York 10467-1402, United States
  • Duke Dermatology Clinic
    Durham, North Carolina 27710-4000, United States
  • The Skin Surgery Center for Clinical Research - Objective Health - PPDS
    Winston-Salem, North Carolina 27103-7109, United States
  • Wake Forest Baptist Health Department of Dermatology - 4618 Country Club Rd
    Winston-Salem, North Carolina 27157-0001, United States
  • ClinOhio Research Services
    Columbus, Ohio 43213-4445, United States
  • Wright State Physicians
    Fairborn, Ohio 45324, United States
  • Apex Clinical Research Center
    Mayfield Heights, Ohio 44124-4005, United States
  • Oregon Medical Research Center PC
    Portland, Oregon 97239-4501, United States
  • University of Pittsburgh Medical Center-3601 5th Ave
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Cumberland Skin Center for Clinical Research - Objective Health - PPDS
    Hermitage, Tennessee 37076-3497, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215-2888, United States
  • Arlington Research Center
    Arlington, Texas 76011-3800, United States
  • UT Physicians Dermatology - Bellaire Station
    Bellaire, Texas 77401-3535, United States
  • Modern Research Associates
    Dallas, Texas 75231-6077, United States
  • North Texas Center for Clinical Research
    Frisco, Texas 75034, United States
  • Austin Institute for Clinical Research, Inc. - Pflugerville - ClinEdge - PPDS
    Pflugerville, Texas 78660-6148, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218-3128, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229-3409, United States
  • Houston Center for Clinical Research, LLC
    Sugar Land, Texas 77479-1001, United States
  • Center For Clinical Studies, LTD. LLP - 451 N Texas Ave
    Webster, Texas 77598-4927, United States
  • Center For Clinical Studies,LTD. LLP - 451 N Texas Ave
    Webster, Texas 77598-4927, United States
  • Virginia Clinical Research - 6160 Kempsville Cir
    Norfolk, Virginia 23507, United States
  • Conexa Investigación Clínica S.A.
    Buenos Aires, C1012, Argentina
  • STAT Research S.A.
    Buenos Aires, C1023AAB, Argentina
  • Instituto de Neumonologia y Dermatologia
    Buenos Aires, C1425BEA, Argentina
  • Centro de Investigacion Clínica - CEDIC
    Ciudad Autónomade Buenos Aires, C1060ABN, Argentina
  • Centro de Investigaciones Médicas Tucumán - PPDS
    San Miguel de Tucumán, T4000, Argentina
  • Medical Center Unimed EOOD
    Sevlievo, Gabrovo 5400, Bulgaria
  • Medical Center Asklepii OOD
    Dupnitsa, Kyustendil 2600, Bulgaria
  • MBAL Skin Systems, Doganovo
    Elin Pelin, Sofia 2115, Bulgaria
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, Sofia-Grad 1431, Bulgaria
  • Diagnostic Consultative Centre - Focus-5 - LZIP EOOD
    Sofia, Sofia-Grad 1463, Bulgaria
  • Medical Center Hera EOOD
    Sofia, Sofia-Grad 1510, Bulgaria
  • Diagnostic Consultative Center XXVIII - Sofia - EOOD
    Sofia, Sofia-Grad 1592, Bulgaria
  • Ambulatory for Specialized Medical Care- Group Practice in Dermatology - Clinic EuroDerma OOD
    Sofia, Sofia-Grad 1606, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
    Sofia, Sofia-Grad 1606, Bulgaria
  • MC Comac Medical - IRN - PPDS
    Sofia, Sofia-Grad 1612, Bulgaria
  • Multiprofile Hospital for Active Treatment - Dobrich AD
    Dobrich, 9300, Bulgaria
  • Multiprofile Hospital For Active Treatment Dr Tota Venkova
    Gabrovo, 5300, Bulgaria
  • Diagnostic Consultative Center Sveti Georgi EOOD
    Haskovo, 6300, Bulgaria
  • Medical Center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • Medical Center Exacta Medica - Vasil Levski 60
    Pleven, 5801, Bulgaria
  • University Multiprofile Hospital for Active Treatment -Dr. Georgi Stranski -Gen. V. Vazov Str 91
    Pleven, Bulgaria
  • Dermatology Research Institute, Inc. - Probity - PPDS
    Calgary, Alberta T3A 2N1, Canada
  • Alberta DermaSurgery Centre - Probity - PPDS
    Edmonton, Alberta T6G 1C2 Canada, Canada
  • VIDA Dermatology - Probity - PPDS
    Edmonton, Alberta T6H 4J8, Canada
  • CaRe Clinic-Red Deer
    Red Deer, Alberta T4N 7C3, Canada
  • Wiseman Dermatology Research Inc. - Probity - PPDS
    Winnipeg, Manitoba R3E 0V9, Canada
  • Brunswick Dermatology Centre - Probity - PPDS
    Fredericton, New Brunswick E3B 1G9, Canada
  • Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity - PPDS
    Hamilton, Ontario L8L 3C3, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • DermEffects - Probity - PPDS
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc - Probity - PPDS
    Markham, Ontario L3P 1X3, Canada
  • DermEdge Research - Probity - PPDS
    Mississauga, Ontario L4Y 4C5, Canada
  • The Centre for Clinical Trials Inc. - Probity - PPDS
    Oakville, Ontario L6J 7W5, Canada
  • Oshawa Clinic-117 King St
    Oshawa, Ontario L1R 1R7, Canada

Showing the first 100 of 217 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2024, 13 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Nov 6, 2023
Primary completionActual
Dec 6, 2024
CompletionActual
Nov 7, 2025
Results delay requested
Oct 2, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06108544
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Nov 6, 2023
Primary completion
Dec 6, 2024
Completion
Nov 7, 2025
Last update
Nov 20, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion